The Newsroom of Vaxine Pty Ltd

Vaxine Press Releases

  • Published on May 15, 2021 - 22:01 GMT

    COVID-19 vaccine breakthrough

    A new multivalent COVID-19 vaccine developed by Australian company Vaxine to tackle the new virus variants could be game-changer in the fight against COVID-19 ADELAIDE, SA, AUSTRALIA, May 16, 2021 /⁨EINPresswire.com⁩/ -- Professor Petrovsky, who is the Chairman and Research Director of Australian-based Vaxine Pty Ltd, explains that the two biggest challenges to tackling the COVID-19 pandemic are to develop a vaccine that completely prevents virus transmission something other COVID-19 have not been …

    Distribution channels: Business & Economy, Chemical Industry ...
  • Published on September 2, 2020 - 23:29 GMT

    Australian government funds $1M for development of Covax-19® vaccine

    Vaxine's Covax-19® vaccine development gets boost from Australian government funding ADELAIDE, SOUTH AUSTRALIA, AUSTRALIA, September 3, 2020 /⁨EINPresswire.com⁩/ -- The pioneering team at Vaxine who developed the world’s first swine flu vaccine in 2009, has been awarded funding of $1 million dollars from the Biomedical Translation Bridge (BTB) program, an initiative of the Medical Research Future Fund operated by MTPConnect, to help advance Vaxine's state-of-the-art COVID-19 vaccine candidate …

    Distribution channels: ...
  • Published on September 1, 2020 - 15:49 GMT

    UK government funding for Oxford Biotech company to work with Australian vaccine company on innovative Covid-19 vaccine

    Vaxine Pty Ltd partners with UK company, Oxford Expression Technologies, on COVID-19 vaccine development LONDON, UNITED KINGDOM, September 2, 2020 /⁨EINPresswire.com⁩/ -- A grant from Innovate UK, part of UK Research and Innovation, has been made to support a partnership between Vaxine Pty Ltd (http://vaxine.net ) who developed the world’s first swine flu vaccine in 2009, and Oxford Expression Technologies (https://oetltd.com). This Innovate UK grant endorses the promise of Covax-19® vaccine, which …

    Distribution channels: Business & Economy, Companies ...
  • Published on August 24, 2020 - 15:05 GMT

    Microsoft’s AI for Health supports COVID-19 vaccine development

    Major Australian/US COVID-19 vaccine collaboration announced AUSTRALIA, August 25, 2020 /⁨EINPresswire.com⁩/ -- Given the global urgency of the COVID-19 pandemic, Microsoft’s AI for Health program has stepped in to support the development and potential deployment of Vaxine’s COVAX-19™ vaccine with a philanthropic grant. Vaxine Pty Ltd, a biotechnology company based in South Australia, uses computational and artificial intelligence (AI)-based technologies to accelerate pandemic vaccine and drug …

    Distribution channels: Companies, Healthcare & Pharmaceuticals Industry ...
  • Published on July 1, 2020 - 11:57 GMT

    First COVID-19 vaccine developed in the Southern Hemisphere commences human trials

    Vaxine's COVAX-19® vaccine becomes the first SARS-CoV-2 (COVID-19) vaccine developed in the Southern Hemisphere to enter human trials. ADELAIDE, SOUTH AUSTRALIA, AUSTRALIA, July 1, 2020 /⁨EINPresswire.com⁩/ -- Australian company, Vaxine Pty Ltd, a clinical stage biopharmaceutical company that specializes in adjuvant platform technology, is behind COVAX-19®, the first SARS-CoV-2 (COVID-19) vaccine developed in the Southern Hemisphere to enter human trials. The Phase 1 trial will provide initial …

    Distribution channels: Business & Economy, Healthcare & Pharmaceuticals Industry ...
  • Published on June 24, 2020 - 05:07 GMT

    Vaxine Pty Ltd announces COVID-19 vaccine collaboration with Kazakh National Agrarian University

    Vaxine executes COVID-19 vaccine memorandum of understanding with the International Centre for Vaccinology at the Kazakh National Agrarian University AUSTRALIA, June 24, 2020 /⁨EINPresswire.com⁩/ -- “Pandemic viruses do not respect national borders and consequently, it is vitally important that scientists from all countries openly work together in a collaborative fashion to counter such global threats”, said Professor Nikolai Petrovsky MBBS, FRACP, PhD, Chairman and Research Director of Vaxine today. “ …

    Distribution channels: Education, Healthcare & Pharmaceuticals Industry ...
  • Published on June 15, 2020 - 05:07 GMT

    Vaxine and University of Georgia Complete First Stage of COVID-19 Ferret Challenge Studies

    COVAX-19® immunizations completed at University of Georgia to assess COVID-19 protection ADELAIDE, SOUTH AUSTRALIA, AUSTRALIA, June 15, 2020 /⁨EINPresswire.com⁩/ -- Vaxine Pty Ltd announced today completion of the immunization phase of ferret challenge studies being conducted at the University of Georgia to test the ability of Vaxine’s promising COVAX-19® vaccine to protect against COVID-19. “We have already seen that COVAX-19® vaccine induces potent antibody and T cell responses against COVID-19 spike …

    Distribution channels: Banking, Finance & Investment Industry, Healthcare & Pharmaceuticals Industry ...
  • Published on May 23, 2020 - 13:45 GMT

    Vaxine Pty Ltd Announces COVID-19 Vaccine Collaboration with Leading South Korean BioPharma Company, Medytox Inc

    Vaxine has entered a collaboration with Medytox Inc., a Korean biopharma company to develop COVAX-19®, Vaxine’s promising vaccine candidate against COVID-19 ADELAIDE, SOUTH AUSTRALIA, AUSTRALIA, May 23, 2020 /⁨EINPresswire.com⁩/ -- Vaxine Pty Ltd., Adelaide, Australia announced today that it has entered into a formal collaboration with Medytox Inc., a Korean stock exchange listed biopharma and development company to accelerate development and commercialisation of COVAX-19®, Vaxine’s promising vaccine …

    Distribution channels: Companies, Healthcare & Pharmaceuticals Industry ...
Contact
Sharen Pringle, Business Manager
Vaxine Pty Ltd
+61 437 033 400
Share This Newsroom
Company/Organization
Vaxine Pty Ltd
1 flinders Drive
Warradale, 5042
Australia
+61 8 8204 4572
Visit Website
About

Vaxine is an Australian vaccine company with 18 years of experience in ultrarapid pandemic vaccine development including against avian influenza, SARS, MERS and Ebola. Its proprietary Advax™ adjuvant technology is a key part of its pandemic vaccines inducing potent T cell and neutralising antibody responses against viral pathogens including in the elderly population who fail to respond to many other vaccines.